Melanoma is a malignant tumor originating from skin melanocytes, involving complex biological and environmental interactions in its pathogenesis. Studies show that although a minority of cases are directly related to genetic factors, the vast majority result from the combined effects of environmental exposure and personal behaviors. Understanding these causes not only helps high-risk groups in prevention but also provides scientific basis for clinical diagnosis and treatment strategies.
The development process of melanoma typically involves key steps such as DNA damage accumulation, uncontrolled cell proliferation, and failure of immune surveillance. UV-induced DNA mutations are the primary trigger, but intrinsic factors such as genetic predisposition and immune system status also play crucial roles. These factors interact, forming a multi-stage carcinogenic process, making the analysis of melanoma's etiology a multi-dimensional approach.
Mutations in genetic genes are significant risk factors for melanoma, with about 10% of patients having a family history. The CDKN2A gene mutation is particularly common; this gene regulates cell cycle and DNA repair, and its defect can lead to ineffective repair of UV-induced DNA damage. Other related genes such as BAP1 and CDK4 have also been linked to familial melanoma, and these mutations may increase skin sensitivity to environmental carcinogens.
If multiple first-degree relatives (parents, siblings) have the disease, individual risk may increase by 5-10 times. Certain populations, such as redheads and individuals with blue eyes and fair skin, have polymorphisms in the MC1R gene that cause abnormal melanin synthesis and reduced ability to repair UV damage. When these genetic backgrounds combine with environmental factors, the carcinogenic risk increases exponentially.
Ultraviolet (UV) radiation is the most definitive environmental trigger for melanoma, with UV-B (280-320 nm) directly damaging DNA and inducing thymine dimers. Long-term accumulated damage that is not repaired can lead to mutations in tumor suppressor genes such as TP53, resulting in loss of apoptosis. Intermittent intense exposure (like sunbathing) is more carcinogenic than chronic uniform exposure, as this pattern tends to cause DNA double-strand breaks.
Geographical differences also highlight the role of environmental factors: high incidence rates are observed in Australia and Nordic countries with high white populations, related to increased UV exposure due to ozone depletion near the Antarctic. Artificial UV sources such as tanning beds and UV tanning devices are also classified as Group 1 carcinogens by the World Health Organization, with usage significantly associated with earlier onset of melanoma.
Personal sun protection habits directly influence disease risk. Lack of daily sun protection measures (such as not using SPF30+ sunscreen or not wearing protective clothing) accelerates DNA damage accumulation. Outdoor workers or outdoor enthusiasts who do not take protective measures have a 2-4 times higher risk of melanoma than the general population.
The immune system status also affects the development of precancerous lesions. Organ transplant recipients on long-term immunosuppressants have a 2-3 times higher risk of melanoma. Conversely, insufficient vitamin D intake may impair skin immune surveillance, indirectly increasing carcinogenic risk. Studies suggest that regular exercise can enhance natural killer cell activity, potentially reducing malignant transformation.
Skin type is an important biological marker. The Fitzpatrick skin type I (fair skin, prone to sunburn and difficult to tan) has a melanoma incidence over 50 times higher than type V (dark skin). A history of severe sunburn, especially blistering sunburns in childhood, increases risk by 83%. Chronic inflammatory environments, such as long-term skin ulcers or wounds, are also associated with tumor development, potentially serving as origins of malignant lesions.
Age is positively correlated with incidence, but certain risk patterns are observed in young patients: a higher proportion of patients aged 20-39 carry genetic mutations. Gender differences include more common lesions on extremities in males, related to skin type and UV exposure patterns. Patients with a history of chemotherapy or radiotherapy have a 2-3 times higher risk of secondary malignancies due to impaired DNA repair mechanisms.
The interaction of multiple factors creates a complex carcinogenic network: genetic susceptibility reduces cellular repair capacity, environmental exposure provides carcinogenic stimuli, and immune surveillance deficiency hampers early clearance of abnormal cells. These combined effects explain why some patients develop melanoma even under relatively low UV exposure environments. Advances in precision medicine, through gene sequencing and environmental exposure tracking, are promoting the development of personalized risk assessment systems.
Prevention strategies should target different risk levels: genetic counseling and gene screening for high-risk families, environmental protection measures (such as sun avoidance behaviors) to block key carcinogenic pathways, and immune modulation therapies as potential early intervention directions. Understanding these causal networks helps establish more effective holistic health management systems.
During self-examination, observe whether moles or patches on the skin are asymmetrical (uneven in size, color, shape), have blurred borders, contain multiple colors (such as black, brown, red), are larger than 6mm in diameter, or change shape rapidly over time. It is recommended to check the entire body under natural light once a month and record any abnormal changes for tracking.
If melanoma has metastasized to other organs, how does the treatment differ?When melanoma metastasizes, systemic therapies are primarily used, including immunotherapy (such as anti-PD-1 monoclonal antibodies) or targeted therapy (drugs targeting specific genetic mutations). In some cases, surgery or radiation therapy may be used to control symptoms. Treatment plans should be tailored by oncologists based on staging and genetic testing results.
Besides applying sunscreen, what additional protective measures can be taken?Avoid prolonged exposure during peak UV hours (10 a.m. to 2 p.m.), and wear wide-brimmed hats, long-sleeved clothing, and UV-protective garments. Use SPF30+ broad-spectrum sunscreens, reapply every 2 hours, and combine physical barriers to reduce UV damage. Blue light from screens does not directly induce melanoma, but prolonged exposure to artificial UV sources should be noted.
For those with a family history of melanoma, how to assess individual risk and undergo regular screening?Individuals with a family history should have professional skin examinations every 3-6 months and inform their doctors of their family history to assess genetic risk. If mutations such as CDKN2A are detected, genetic counseling can help develop more intensive follow-up plans. Daily sun avoidance and monitoring any new or changing moles are essential.
Is it true that "darker skin is less susceptible to melanoma"?This statement is not entirely accurate. Although melanin provides some protection against UV rays, individuals with darker skin can still develop melanoma due to genetic mutations or chronic damage, often occurring on extremities (such as palms and soles). Medical advice recommends that all populations remain vigilant for abnormal skin lesions, and not ignore examinations due to skin color, especially paying attention to changes in non-sun-exposed areas.
%201.svg)
Copyright © 2025 MedFrontiers. All Rights Reserved.
